P663: HEALTH-RELATED QUALITY OF LIFE OUTCOMES ASSOCIATED WITH ZANUBRUTINIB VS IBRUTINIB MONOTHERAPY IN PATIENTS WITH RELAPSED/REFRACTORY (RR) CLL/SLL: RESULTS FROM THE RANDOMIZED PHASE 3 ALPINE TRIAL

• P. Hillmen,
• J. Brown,
• N. Lamanna,
• S. O’Brien,
• C. Tam,
• L. Qiu,
• K. Yang,
• G. Barnes,
• K. Wu,
• T. Salmi,
• B. Eichhorst

Affiliations

P. Hillmen

1 St James’s University Hospital, Leeds, United Kingdom

J. Brown

2 Medical Oncology, Dana-Farber Cancer Institute, Boston

N. Lamanna

3 Herbert Irving Comprehensive Cancer Center, Columbia University, New York

S. O’Brien

4 Chao Family Comprehensive Cancer Center, University of California, Irvine, United States of America

C. Tam

5 Peter MacCallum Cancer Centre, Melbourne

L. Qiu

9 Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China

K. Yang

10 BeiGene USA, Inc., San Mateo, United States of America

G. Barnes

10 BeiGene USA, Inc., San Mateo, United States of America

K. Wu

10 BeiGene USA, Inc., San Mateo, United States of America

T. Salmi

11 BeiGene Switzerland GmbH, Basel, Switzerland

B. Eichhorst

12 Department of Internal Medicine, University of Cologne, Center for Integrated Oncology Aachen, Cologne, Germany